Mode
Text Size
Log in / Sign up

Narrative review suggests MRgFUS reduces lesion size and symptoms in women with adenomyosisMagnetic resonance-guided focused ultrasound surgery helps reduce lesion size and ease symptoms for women with adenomyosis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that MRgFUS may reduce lesion size and symptoms in adenomyosis, though comprehensive comparative data are lacking.

This narrative review evaluates the role of magnetic resonance-guided focused ultrasound surgery (MRgFUS) as a treatment option for adenomyosis in women of childbearing age. The publication does not report a specific sample size or follow-up duration. Instead, it synthesizes qualitative findings regarding the procedure's potential benefits.

The authors indicate that MRgFUS can effectively reduce lesion size and alleviate symptoms associated with the condition. The review does not provide specific effect sizes, absolute numbers, or statistical measures such as p-values or confidence intervals for these outcomes.

A key limitation acknowledged by the authors is that no comprehensive synthesis comparing ablation techniques and guidance modalities specifically for adenomyosis currently exists. The review concludes that MRgFUS is expected to evolve into a more individualized and precise therapeutic strategy and help establish standardized frameworks for patient selection and outcome prediction.

Safety data, including adverse events, serious adverse events, and tolerability, were not reported in this narrative review. Consequently, the practice relevance relies on the expectation that the procedure will become more standardized rather than on immediate comparative safety data.

Adenomyosis is a condition where the tissue that lines the uterus grows into the muscle wall. This can cause heavy bleeding and painful periods. Many women of childbearing age struggle with these symptoms and seek treatment options. One option is magnetic resonance-guided focused ultrasound surgery, often called MRgFUS. This procedure uses sound waves to heat and destroy the damaged tissue without making a large cut.

The review shows that MRgFUS can effectively reduce the size of the problem areas inside the uterus. When the tissue shrinks, it often leads to fewer painful periods and less heavy bleeding. Patients may feel better overall after the treatment. The procedure is done while the patient is awake and usually takes only a few hours to complete.

However, more research is needed to compare this method with other treatments. There are no complete studies yet that compare different ways to guide the sound waves or compare MRgFUS to other ablation techniques specifically for adenomyosis. Doctors hope this technology will become more precise over time. Future work should focus on creating clear rules for picking the right patients and predicting how well the treatment will work for each person.

What this means for you:
MRgFUS shrinks lesion size and eases symptoms, but better methods for patient selection and outcome prediction are needed.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Adenomyosis (AM) is a common gynecological disorder with high prevalence among women of childbearing age. Although hysterectomy is the definitive treatment, it is considered unsuitable for patients who wish to preserve fertility, creating an urgent need for effective, minimally invasive alternatives. Despite emerging evidence, no comprehensive synthesis comparing ablation techniques and guidance modalities specifically for AM currently exists. Currently used thermal ablation techniques include high-intensity focused ultrasound (HIFU), radiofrequency ablation, and percutaneous microwave ablation. Among these, HIFU has gained increasing attention as a non-invasive, uterus-sparing treatment option. Focused ultrasound procedures can be performed under ultrasound or magnetic resonance imaging (MRI) guidance. Magnetic resonance-guided focused ultrasound surgery (MRgFUS), leveraging the high resolution of MRI, enables more precise lesion targeting, real-time temperature monitoring, and immediate postoperative assessment. MRgFUS can effectively reduce lesion size and alleviate symptoms, while lesion-specific MRI features and radiomics models show predictive value for treatment outcomes. By integrating adjuvant hormonal therapies and advanced imaging evaluations, MRgFUS is expected to not only evolve into a more individualized and precise therapeutic strategy but also help establish standardized frameworks for patient selection and outcome prediction. This review summarizes recent advances in MRgFUS for the treatment of AM, focusing on its unique advantages, safety, and efficacy, and emphasizes the critical role of MRI-based imaging biomarkers in predicting therapeutic outcomes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.